July 2, 2020 09:44 AM EDTUpdated 10:23 AM
News Briefing

Bio­gen bags an AAV gene ther­a­py pro­gram from Mass­a­chu­setts Eye and Ear; Biotechs raised $1B-plus in lat­est round of fol­low-ons

John Carroll

Editor & Founder

→ Bio­gen has picked up a new, pre­clin­i­cal gene ther­a­py pro­gram from Mass­a­chu­setts Eye and Ear for in­her­it­ed reti­nal de­gen­er­a­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times